For research use only. Not for therapeutic Use.
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies[1][2].
| Catalog Number | I041525 |
| CAS Number | 1820660-69-2 |
| Purity | ≥95% |
| Reference | [1]. Tahir SK, et al. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023 Jan 30:blood.2022017333. [2]. Silva A S, et al. Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma. Blood, 2020, 136(Supplement 1):49-50. |
